A volunteer study suggested that taking paracetamol 4 g daily could result in elevated alanine aminotransferase plasma levels in a substantial proportion of healthy volunteers. The safety of this dose of paracetamol for acute postoperative pain remains controversial. This study aimed to examine the incidence of alanine aminotransferase elevations after short-term use of paracetamol 4 g daily, as part of the standard pain management protocol, for 93 consecutive patients after cardiothoracic surgery. Alanine aminotransferase levels and other liver function tests were measured preoperatively as baseline and once daily after surgery during the intensive care unit stay. Preoperative alanine aminotransferase levels of more than one time the upper limit of normal (ULN, >40 U/l) was observed in 11% (n=10) of the patients but none of these baseline alanine aminotransferase levels exceeded three times the ULN (>3×ULN) . The average daily dose of paracetamol administered was 50 mg/kg (SD=16) after surgery. Postoperative alanine aminotransferase levels of >1×ULN was observed in 17% (n=16), and 4% (n=4) exceeded >3×ULN. The other liver function tests of the latter four patients, including aspartate aminotransferase (range 173 to 5590 U/l), γ-glutamyltransferase (range 56 to 103 U/l), lactate dehydrogenase (range 376 to 3518 U/l) and the International Normalised Ratio (range 2.0 to 6.6), were all abnormal. These four patients all had right ventricular failure or cardiogenic shock during the postoperative period which could explain the significant rises in alanine aminotransferase after surgery. In conclusion, the incidence of significant alanine aminotransferase elevations after using daily paracetamol as an analgesic agent for cardiac surgery, at a dose of 4 g per day, was low and mostly due to complications after surgery. Our results, albeit still very limited, provided some reassurance about the safety of paracetamol 4 g daily, as a supplementary analgesic agent for adult patients undergoing cardiac surgery.
Paracetamol is the most commonly used analgesic agent to treat mild to moderate postoperative pain 1 . For more severe pain, paracetamol in combination with an opioid produces a greater analgesic effect than higher doses of the opioid alone [2] [3] [4] . Moreover, paracetamol has few contraindications or side-effects and lacks significant drug interactions 5 , which makes it a valuable analgesic for postoperative pain management (e.g. after cardiothoracic surgery). Severe hepatotoxicity may, however, occur in significant paracetamol overdoses (>140 mg/kg) 6 through an increased production of the reactive metabolite N-acetylbenzoquinoneimine which reacts with the cysteine group of hepatocellular proteins, resulting in hepatic cell death.
Although hepatotoxicity (defined as alanine aminotransferase [ALT] levels >1000 U/l) 7 after therapeutic dosages of paracetamol has not been not reported 8, 9 , Watkins and colleagues 10 observed a high incidence of alanine aminotransferase elevations (31 to 44%) of more than three times the upper limit of normal (ULN) in paracetamol-treated healthy subjects after three days of its use. In this clinical trial, a total of 145 healthy subjects were randomly assigned into five groups (placebo vs either paracetamol 4 g daily, or a combination of paracetamol with one of three different opioids). As a result of this publication, physicians and pharmacists are now well aware of possible liver injury associated with therapeutic dosage of paracetamol for the treatment of acute and chronic pain 6, 11, 12 . If an elevated ALT level can be observed in healthy subjects after taking 4 g of paracetamol per day, it is possible that this problem can be more prevalent for critically ill patients due to concomitant use of drugs that may affect the liver and impaired perfusion of the liver, especially in postoperative cardiothoracic patients after cardiopulmonary bypass 13 . Although other analgesic agents, such as non-steroidal antiinflammatory drugs or opioids, are also available, these agents also have significant side-effects and may not be safer than paracetamol 6 . As such, it is important to evaluate the safety profile of paracetamol as an analgesic agent for critically ill patients. Currently the incidence of ALT elevations after using paracetamol as part of an analgesic protocol after cardiothoracic surgery remains uncertain 14 . In this study we aimed to evaluate the profile of ALT levels, in a cohort of postoperative cardiothoracic patients who had been treated with rectal or intravenous paracetamol 4 g daily.
METHODS AND MATERIALS

Study design
A prospective observational study was performed in a 30-bed surgical/medical intensive care unit (ICU) in a teaching hospital, St Antonius Hospital, Nieuwegein, The Netherlands. The study was part of a clinical trial (registered at ClinicalTrials.gov, identifier NCT00558090), in which the pain management for intervention-related pain was evaluated in postoperative cardiothoracic patients. The clinical trial was approved by the local Ethics Committee of the St Antonius Hospital (approval number R0715A, 7 November 2007). Written informed consent was obtained from the patients before the cardiothoracic surgical procedure.
Patients
Between 18 February and 13 November 2008, 135 consecutive patients aged between 18 and 85 years were admitted to the ICU after cardiothoracic surgery requiring sternotomy and cardiopulmonary bypass. Exclusion criteria were patients with a known morphine or paracetamol allergy, planned admission to the postoperative anaesthesia care unit, pregnancy or breast-feeding, serious neurological deficits (e.g. coma or brain death), patients not able to communicate in either Dutch or English and patients who refused informed consent. In 93 of the 135 patients, we were able to collect ALT and aspartate aminotransferase (AST) values and were therefore included in this prospective observational study.
Standard pain titration protocol for treatment of pain at rest
According to standard care in our ICU, physicians and nurses were trained in assessing pain and in providing adequate analgesia. A patient data management system obliged nurses to ask patients for their pain score three times a day and the preferred analgesic treatment was optimised 15 .
For basic pain relief, a standard pain titration protocol was used in all patients, which has been the practice in the ICU since 2007, consisting of a continuous intravenous infusion of morphine and a standard dose of rectal or intravenous paracetamol 4 g daily ( Figure 1 ).
Liver function tests
Arterial blood plasma samples (4 ml) for determination of ALT and AST were taken from the arterial line. For each patient, samples were obtained just after the induction of anaesthesia (baseline) and thereafter once daily at 1500 hours as long as the patients were still in the ICU, for a maximum of 10 days. The results of the liver function test were available to the attending clinicians. The ULN for both ALT and AST was defined as 40 U/l 10 , in which 2×ULN=80 U/l and 3×ULN=120 U/l. Other liver function tests, such as γ-glutamyl transpeptidase, lactate dehydrogenase, International Normalised Ratio and bilirubin were taken as part of routine clinical care.
Study procedure
On the day of cardiothoracic surgery, patients received 1 g of paracetamol orally. Thereafter, patients received rectal or intravenous paracetamol upon automatic signals by the patient data management system four times a day, seven days a week. When patients were transferred to the ward, paracetamol 1 g four times daily was prescribed in the ICU-discharge letter for the ward.
Data analysis
The SPSS statistical package (version 15.0.1 for Windows; SPSS, Chicago, IL, USA) was used for the statistical analyses. Descriptive statistics are reported as mean with standard deviation, median with range or proportion. Means were compared using a t-test for normally distributed data or the nonparametric 
RESULTS
Patients and data
Patient demographics of the 93 patients are presented in Table 1 . The mean number of measured ALT tests performed per patient was 3.4 (range 2 to 8). Of the 93 patients included in this study, eight patients (9%) used preoperative paracetamol 4 g daily. In 69 patients, information on history of alcohol use was available, of whom 36% (n=25) used alcohol (>1 unit daily) preoperatively. The mean dose of paracetamol administered in the ICU per day for all patients was 50 mg/kg (SD=16).
Preoperative ALT levels
Ten patients (11%) had a baseline ALT level of more than one times the upper limit of normal (>1×ULN) (mean ALT 66 U/l, range 42 to 96). In three of these 10 patients, the ALT levels were elevated to >2×ULN (81 U/l, 90 U/l and 96 U/l). None of the patients had a preoperative ALT level of >3×ULN (Table 2, Figure 2 ).
Postoperative ALT levels
In Table 2 and Figure 2 , the incidences of aminotransferase levels (ALT and AST) by multiples of the ULN (>40 U/l) (A) and the incidence of aminotransferase levels (ALT and AST) by multiples of patient's baseline aminotransferase levels (B) are presented.
Cases with an ALT >1×ULN (>40 U/l)
Of the 93 patients included in the study, the incidence of ALT >1×ULN and >2×ULN was 17% (n=16) and 5% (n=5), respectively. Four male patients (4%) developed an ALT >3×ULN (Table 2, Figure 2 ).
In patients with an ALT >1×ULN (n=16), mean dose of paracetamol per day was 50 mg/kg (SD= 22 mg/kg). The mean cumulative dose of paracetamol received in ICU in these patients was 205 mg/kg (SD=110 mg/kg).
Cases with an ALT >2×ULN (>80 U/l)
In total, 5% (n=5) of patients developed an ALT >2×ULN. One of these patients had a 
Incidence of aminotransferase elevations by multiples of upper limit of normal (A) and the incidence of aminotransferase elevations by multiples of patients' preoperative/baseline (B)
Total, n Preoperative levels, n (%) Postoperative levels, n (%) maximum ALT of 93 U/l, which decreased to normal (<40 U/l) during follow-up and the other four patients experienced ALT values of more than three times the upper limit of normal (>3×ULN).
Cases with an ALT of >3×ULN (>120 U/l) Table 3 presents an overview of the four cases with an ALT of >3×ULN. In all four cases, other liver function tests (e.g. AST, γ-glutamyl transpeptidase, lactate dehydrogenase, International Normalised Ratio) and also creatine kinase were increased. All four cases also had an elevated AST postoperatively (>3×ULN, range 173 to 5590 U/l).
Case 1 had a preoperative ALT baseline of 60 U/l, which is >1×ULN. Case 1 experienced an allergic reaction to protamine administered during surgery, leading to right ventricular failure. The postoperative course of this patient was further complicated by S. aureus pneumonia. The patient recovered promptly after treatment with inotropic agents and antibiotic therapy and left the ICU four days postoperatively. Cases 2, 3 and 4 had a preoperative baseline ALT level within the reference range (<40 U/l) and developed cardiogenic shock and/or sepsis postoperatively and died two to five days later. In case 4, paracetamol was discontinued when the ALT level was 1011 U/l on day four of ICU stay.
One of the four cases with an ALT of >3×ULN used paracetamol 4 g daily preoperatively. This case had no serious increase in ALT and AST levels at preoperative baseline (60 U/l and 35 U/l respectively). None of the four cases with an ALT of >3×ULN used alcohol preoperatively.
DISCUSSION
Our results showed that the incidence of maximum ALT of >3×ULN after paracetamol 4 g daily in patients after cardiothoracic surgery was low (4%, n=4) and the significant rises in ALT could easily be explained by severe complications after surgery.
The safety of using 4 g per day of paracetamol as an analgesic and antipyretic agent remains controversial 9 . Increased ALT levels after receiving standard therapeutic doses of paracetamol for various indications have been reported [16] [17] [18] [19] and in a systematic review Dart and Bailey reported an overall incidence of 0.4% increase in ALT levels in patients who were treated with therapeutic doses of paracetamol 9 . Furthermore, a remarkably high incidence of increased ALT levels was also reported in a healthy volunteer study 10 . In some reports, the use of therapeutic doses of paracetamol also appeared to have contributed to the development of severe liver failure and death [20] [21] [22] . Our study differs from these previous reports: first, we had careful documentation of the doses of paracetamol administered to all the patients in this study. It is possible that some of the previous reports of severe liver toxicity induced by paracetamol may be due to unintended overdoses because of inaccurate documentation of the doses of paracetamol used 9 . In fact, a number of prospective randomised clinical trials on healthy subjects also did not observe significant ALT elevations after 4, 6 or 8 g of paracetamol per day for a maximum of three days 23, 24 , even in subjects using alcohol 25 .
Second, although mild elevations of ALT were not uncommon after therapeutic doses of paracetamol after cardiac surgery, severe elevations of ALT (3×ULN) were all associated with significant complications during or after cardiac surgery. It is known that in critically ill patients, the main causes of liver failure are septic shock and a low cardiac output, i.e. cardiogenic shock 26 . In cardiac failure, a low cardiac output causes hepatic ischaemia due to reduced hepatic blood flow and venous congestion of the liver 26 . In sepsis, liver failure is mainly the result of insufficient oxygen extraction of the liver despite sufficient or even increased splanchnic and hepatic perfusion 26 . In these conditions of liver failure, liver function parameters like AST, γ-glutamyl transpeptidase, lactate dehydrogenase, International Normalised Ratio and bilirubin are often increased, similar to those we observed in our four cases in our study (Table 3 ). Therefore, the increased ALT levels in these four cases differ from the typical paracetamol induced liver injury, in which an isolated increase in ALT and AST levels within the first 24-hour period is observed 27 .
Third, in the healthy volunteer study conducted by Watkins and colleagues 10 , they included no data on alcohol consumption, diet or paracetamol use before entering the study. We were able to collect these data and observed that 37% (n=25) and 9% (n=8) of the patients regularly consumed alcohol or used paracetamol preoperatively, respectively, in this study. Of the four patients with ALT levels of >3×ULN, only one patient used preoperative paracetamol 1 to 4 g daily. However, baseline ALT (60 U/l) and AST (35 U/l) levels for this patient were not substantially increased.
Apart from an increase in ALT levels in our patients, we also observed an increase in AST levels in many of our patients after surgery (AST of >1×ULN: 82%, >2×ULN: 43% and >3×ULN: 15%). Because AST is also a biomarker for myocardial injury, and is formed in the urea cycle after cardiac ischaemia 28 , it is possible that increases in AST were primarily due to myocardial ischaemia during and after surgery.
STUDY STRENGTHS AND LIMITATIONS
This study has some limitations. First, the sample size of this study was small and was underpowered to detect rare adverse events. Second, we did not have a control group in our observational study. The safety of paracetamol should ideally be tested in a randomised placebo-controlled trial in which selection bias and confounding can be reduced. Third, we used different routes to administer paracetamol to the patients during the course of their stay in ICU. Because bio-availability of rectal paracetamol is not the same as intravenous or oral paracetamol, it is possible that the incidence of liver dysfunction would be higher if only intravenous preparation of paracetamol was used. Finally, we did not have blood paracetamol levels both before and after the occurrence of deranged liver function tests. As such, we cannot assess whether there was any significant relationship between blood paracetamol concentrations and ALT levels in our patients.
CONCLUSION
In our cohort of postoperative cardiothoracic patients, we found a low incidence of substantial ALT elevations, except in those who had severe cardiac complications during or after surgery, and this did not appear to affect the clinical outcomes of our patients. With the limited data available, this study provided some reassurance about the safety of therapeutic doses of paracetamol in adult cardiac surgical patients.
